Form 13-F position report

SUMMIT THERAPEUTICS INC

Reported by BAKER BROS ADVISORS LP

SMMT CUSIP 86627T108 Manager CIK 0001263508

Reported 32,786,348 shares, unchanged from the prior quarter.

Reported value 16.1%; share count 0.0% vs. the prior quarter.

Unchanged
% of reported 13F value 2.63% This manager · Q3 2026
Shares 32,786,348 Quarter-end amount reported
Reported value $554,417,145 Fair value at quarter end
Consecutive quarters held 10 Through Q3 2026

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2022-12-31 8500000
2023-03-31 11033234
2023-06-30 15824810
2023-09-30 5872685
2023-12-31 0
2024-06-30 181133332
2024-09-30 534904544
2024-12-31 435861716
2025-03-31 471155646
2025-06-30 717624887
2025-09-30 696716643
2025-12-31 636479692
2026-03-31 689974554
2026-06-30 477697090
2026-09-30 554417145

Quarterly position history

How this manager's reported quarter-end position changed over time.

15 quarters
Quarterly reported position history for SUMMIT THERAPEUTICS INC held by BAKER BROS ADVISORS LP.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2026 Unchanged 32,786,348 0 (0.0%) 2.63% $554,417,145 2026-11-16
Q2 2026 Reduced 32,786,348 -3,604,715 (-9.9%) 2.39% $477,697,090 2026-08-14
Q1 2026 Unchanged 36,391,063 0 (0.0%) 3.96% $689,974,554 2026-05-15
Q4 2025 Added 36,391,063 +2,668,089 (7.9%) 3.73% $636,479,692 2026-02-17
Q3 2025 Unchanged 33,722,974 0 (0.0%) 5.03% $696,716,643 2025-11-14
Q2 2025 Added 33,722,974 +9,298,109 (38.1%) 6.96% $717,624,887 2025-08-14
Q1 2025 Unchanged 24,424,865 0 (0.0%) 5.21% $471,155,646 2025-05-15
Q4 2024 Unchanged 24,424,865 0 (0.0%) 4.66% $435,861,716 2025-02-14
Q3 2024 Added 24,424,865 +1,202,643 (5.2%) 5.54% $534,904,544 2024-11-14
Q2 2024 New 23,222,222 +23,222,222 (0.0%) 2.31% $181,133,332 2024-08-14
Q4 2023 Reduced 0 -3,140,473 (-100.0%) 0 $0 2024-02-14
Q3 2023 Reduced 3,140,473 -3,164,232 (-50.2%) 0.03% $5,872,685 2023-11-14
Q2 2023 Unchanged 6,304,705 0 (0.0%) 0.09% $15,824,810 2023-08-14
Q1 2023 Added 6,304,705 +4,304,705 (215.2%) 0.06% $11,033,234 2023-05-15
Q4 2022 New 2,000,000 +2,000,000 (0.0%) 0.05% $8,500,000 2023-02-14

Who else reported the position

334 managers reported SUMMIT THERAPEUTICS INC for Q3 2026.

Managers reporting SUMMIT THERAPEUTICS INC in Q3 2026.
Manager Activity Shares Change % of reported 13F Reported value Tenure
BAKER BROS ADVISORS LP This report Unchanged 32,786,348 0 2.63% $554,417,145 10 qtrs
BlackRock Inc Added 10,363,750 +834,709 < 0.01% $175,251,012 9 qtrs
FMR LLC Reduced 8,136,745 -1,907,202 < 0.01% $137,592,355 14 qtrs
VANGUARD CAPITAL MANAGEMENT LLC Added 7,230,441 +1,495,957 < 0.01% $122,266,757 3 qtrs
VANGUARD PORTFOLIO MANAGEMENT LLC Added 6,717,642 +1,675,452 < 0.01% $113,595,326 3 qtrs
STATE STREET CORPORATION Reduced 6,093,474 -3,443,322 < 0.01% $103,040,645 16 qtrs
PRICE T ROWE ASSOCIATES INC MD Added 5,296,215 +1,402,395 < 0.01% $89,560,000 14 qtrs
CITADEL ADVISORS LLC Added 3,783,589 +2,057,873 < 0.01% $63,980,490 11 qtrs
GEODE CAPITAL MANAGEMENT LLC Added 3,489,224 +61,961 < 0.01% $59,015,572 25 qtrs
Kynam Capital Management LP Added 3,000,000 +1,800,000 2.81% $50,730,000 2 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2026
Filed
November 16, 2026
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
32,786,348
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.